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Abstract
Purpose The main metabolic pathways of oxycodone, a
potent opioid analgetic, are N-demethylation (CYP3A4) to
inactive noroxycodone and O-demethylation (CYP2D6) to
active oxymorphone. We performed a three-way, placebo-
controlled, double-blind cross-over study to assess the
pharmacokinetic and pharmacodynamic consequences of
drug interactions with oxycodone.
Methods The 12 participants (CYP2D6 extensive metabo-
lizers) were pre-treated with placebo, ketoconazole or
paroxetine before oral oxycodone ingestion (0.2 mg/kg).
Results Pre-treatment with ketoconazole increased the AUC
for oxycodone 2- to 3-fold compared with placebo or
paroxetine. In combination with placebo, oxycodone induced
the expected decrease in pupil diameter. This decrease was
accentuated in the presence of ketoconazole, but blunted by
paroxetine. In comparison to pre-treatment with placebo,
ketoconazole increased nausea, drowsiness, and pruritus
associated with oxycodone. In contrast, the effect of pre-
treatment with paroxetine on the above-mentioned adverse
events was not different from that of placebo. Ketoconazole
increased the analgetic effect of oxycodone, whereas
paroxetine was not different from placebo.
Conclusions Inhibition of CYP3A4 by ketoconazole
increases the exposure and some pharmacodynamic effects
of oxycodone. Paroxetine pretreatment inhibits CYP2D6
without inducing relevant changes in oxycodone exposure,
and partially blunts the pharmacodynamic effects of oxy-
codone due to intrinsic pharmacological activities. Pharma-
codynamic changes associated with CYP3A4 inhibition may
be clinically important in patients treated with oxycodone.
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Introduction
Oxycodone (6-deoxy-7,8-dehydro-14-hydroxy-3-O-methyl-
6-oxymorphine) is a semi-synthetic opioid analgetic used
frequently for the treatment of moderate to severe pain [1],
including postoperative pain [2] or pain associated with
cancer [3]. Despite having been developed more than
90 years ago as an alternative to heroine, some aspects of
its pharmacodynamic characteristics and of its biotransfor-
mation have only recently been the subject of research or
still remain unclear.
Oxycodone has an analgetic potency of approximately 2
relative to morphine [4, 5] and reveals affinity primarily for
μ-opioid receptors [1]. After oral administration, its
bioavailability in humans is between 60 and 87% and its
elimination half-life 3–5 h [1]. Oxycodone is heavily
metabolized with less than 10% of the orally administered
drug excreted unchanged in the urine [6].
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Biotransformation occurs in the liver by different cyto-
chrome P450 isoenzymes (CYP) [7]. Most of the drug is N-
demethylated by CYP3A4 to noroxycodone (5α-4,5-epoxy-
14-hydroxy-3-methoxymorphinan-6-one) (Fig. 1). A smaller
amount is O-demethylated by CYP2D6 to the active
metabolite oxymorphone (4,5α-epoxy-3,14-dihydroxy-17-
methylmorphinan-6-one), exhibiting about 40 times the
affinity and 8 times the potency on μ-opioid receptors
compared with the mother substance [1, 7]. Oxymorphone
itself is also marketed as an analgetic and is used primarily
for cancer pain management and in obstetrics [8].
Considering the strong pharmacodynamic effects of
oxymorphone, it is surprising that suppression of the
production of oxymorphone through inhibition of CYP2D6
by quinidine did not substantially alter the pharmacody-
namic effects of oral oxycodone [9]. This may be explained
by the low plasma concentrations of oxymorphone reached
in persons treated with oxycodone [9, 10]. On the other
hand, since oxycodone had more pronounced analgetic
activity in CYP2D6 extensive compared with poor metab-
olizers under experimental conditions, the formation of
oxymorphone may contribute to its analgetic activity in
CYP2D6 extensive metabolizers [11]. This analgetic effect
associated with CYP2D6 may not be clinically relevant;
however, since the postoperative pain control by oxycodone
was not significantly different between CYP2D6 poor and
extensive metabolizers [12]. In contrast to oxymorphone,
noroxycodone, quantitatively the most important metabolite
of oxycodone, has only a low affinity for μ-opioid receptors
and a low analgetic potency [10]. In vitro, inhibition of
CYP3A4 with ketoconazole reduced the formation of
noroxycodone by >90% [7]. Recent studies in humans
have shown that inhibition of CYP3A4 by voriconazole
[13] or telithromycin [14] increased exposure and the
pharmacodynamic effects of oral oxycodone. Accordingly,
CYP3A4 induction by rifampicin has recently been shown
to decrease the exposure to intravenous or oral oxycodone
and to attenuate its pharmacological effects [15].
The aim of the study was to investigate the effects of
CYP2D6 and CYP3A4 inhibition on oxycodone kinetics
and dynamics in the same individuals. For this purpose, we
used the SSRI paroxetine as a CYP2D6 [16] and
ketoconazole as a CYP3A4 inhibitor [7]. Regarding the
study aim, it is important to realize that the clinical part of
the study had been planned and conducted before the
studies describing the effect of CYP3A4 inhibitors [13, 14]
or inducers [15] were published.
Materials and methods
Study subjects
The 14 subjects selected for the study had to be non-
smokers aged between 18 and 50 years (median
age ± standard deviation 25±7 years, range 21 to 41 years)
and CYP2D6 extensive metabolizers. They all had a normal
physical examination, normal blood pressure, body weight
within 15% of ideal (weight 72±7 kg, height 181±5 cm,
body mass index 22±2 kg/m2), normal electrocardiogram
and normal routine blood chemistry. They had to abstain
from ingestion of drugs (including herbal drugs), grapefruit
juice, and beverages containing caffeine during the whole
study period. For CYP2D6 genotyping, an EDTA blood
sample was obtained from which genomic DNA was
extracted using the Promega DNA purification kit
(Dübendorf, Switzerland). The DNA was analyzed for
CYP2D6 polymorphisms and gene duplications using
real-time PCR, as described by Müller et al. [17]. Only
probands with the *1/*1 genotype were included in the study.
They were all extensive metabolizers as assessed using dextro-
metorphan as a probe drug [18]. A drug screen in the urine
was performed to identify and exclude active drug users.
Drugs used in the study
Oxycodone was obtained as an oral solution with a dosing
syringe (OxyNorm®, 10 mg/ml) from Mundipharma
(Basel, Switzerland). Ketoconazole was purchased as 200-
mg tablets (Nizoral®) from Janssen-Cilag (Baar, Switzer-
land) and paroxetine as 20-mg tablets (Deroxat®) from
GlaxoSmithKline (Münchenbuchsee, Switzerland). To ensure
blinding, the tablets were filled into capsules; identical
capsules containing only lactose served as placebo. All the
capsules used were prepared by the local hospital pharmacy.
Study design
The study was conducted according the principles of the
declaration of Helsinki, was approved by the Ethics
Committee of the State of Basel, and was notified by the
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Fig. 1 Oxycodone structure and
metabolism. The main metabolic
pathway of oxycodone is the
formation of the pharmacologi-
cally inactive noroxycodone by
CYP3A4
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Swiss Drug Regulatory Agency (Swissmedic). The selected
volunteers had to understand the design of the study and to
give written informed consent before undergoing any
study-related procedures. The study was designed as a
randomized, double-blind, three-way cross-over, single-
center trial that was performed at the Phase I Study Center
of the University Hospital Basel. The study endpoints were
the effect of ketoconazole and paroxetine on the area under
the plasma concentration–time curve (AUC) and on the
pharmacodynamic variables (see below) of oxycodone.
Subjects were randomized to one of the three double-
blinded pretreatments (placebo, ketoconazole 200 mg or
paroxetine 20 mg), which had to be ingested 48 h, 24 h, and
1 h before oral ingestion of oxycodone (0.2 mg/kg body
weight). Subjects had to stay within the study center for the
first 14 h after ingestion of oxycodone. A light breakfast
was served after the administration of oxycodone and a
light meal at 5 h. The intake of alcohol and/or xanthine-
containing food and/or beverages as well as grapefruit and/
or grapefruit juice was not allowed from 48 h before till
48 h after oxycodone ingestion.
Before and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24,
36, and 48 h after ingestion of oxycodone, 7.5 ml of blood was
withdrawn through a catheter placed in a vein of the forearm
into heparin-coated tubes. Plasma was separated and stored
at −70°C pending analysis. Subjects underwent static and
dynamic pupil assessments, cold pressor tests, and VAS-based
recordings of subjective effects pre-dose as well as 2, 4, 6, 8,
and 12 h post-dose. At 12 h post-dose, subjects were
discharged from the Study Center and returned the following
days for the final blood samplings. A wash-out period of
14 days followed the treatment phases.
Quantification and pharmacokinetics of oxycodone,
noroxycodone, and oxymorphone
Plasma concentrations of oxycodone and its two major
metabolites were determined by LC-MS, as described by
Neuvonen et al. [19]. The LOQs of the method were 0.1 ng/
mL for oxycodone and 0.25 ng/mL for oxymorphone and
noroxycodone. The standard curves were linear up to
50 ng/mL. The inter- and intra-day precisions were <15%
at low (0.5 ng/mL) and high concentrations (50 ng/mL) of
oxycodone and its metabolites.
The pharmacokinetic variables of oxycodone were either
obtained directly from the individual plasma concentrations
(Cmax and tmax) or calculated with non-compartmental
analysis using WinNonlin (Pharsight Corporation, Moun-
tain View, CA, USA; AUC0-t, AUCt1, λz and t1 2= ), as
described previously [20].
For noroxycodone and oxymorphone, only the Cmax
values are provided, which were obtained from the rough
data as described above for oxycodone.
Static and dynamic pupillometry
Subjects were examined with a desktop pupillometer, the
Compact Integrated Pupillograph (CIP; Amtech, Hamburg,
Germany). This system uses an infrared camera to monitor a
subject’s eye, generates a gray-scale image of it, and computes
a luminosity histogram over a line crossing the equator of the
image. A separate room was furnished for this test with
constant lighting conditions and reduced ambient noise.
Subjects were asked, after a 5-min period of rest inside the
room, to place their head onto the head rest of the apparatus
and to stare into the distance so as to eliminate the miosis that
accompanies the accommodation reflex. After having put the
subject’s eye into focus, a light stimulus of 250 ms was
applied, inducing the pupillary light reflex, which was
recorded using the integrated software. Four measurements
of good quality were obtained for each session with 30 s
relaxation time for dark adaptation between the runs.
The plotted raw data still contained low amplitude system
noise from the individual measurements. To correct for these,
a Savitzky–Golay nine-point smoothing algorithm [21] was
implemented in Excel, ultimately yielding a single smooth
curve representing the pupillodynamics of one time point
(Fig. 2). The following parameters were extracted from the
smoothed median curves: initial diameter of the pupil,
latency until first light reaction of the pupil, amplitude of
the light reaction, time to maximal constriction of the pupil,
and the time to one-third redilatation.
Analgesia
Cold pressor testing was used to measure pain tolerability
[10, 22]. A water receptacle was filled with cold water and
Fig. 2 Dynamic pupillometry. Subjects were studied under constant
lighting conditions and reduced ambient noise. A light stimulus of
250 ms was applied, inducing the pupillary light reflex, which was
recorded and evaluated as described in the figure and in Materials and
methods
Eur J Clin Pharmacol (2011) 67:63–71 65
crushed ice and stirred until a temperature of 1±0.5°C was
achieved. Subjects placed their non-dominant hand in the
water bath with fingers spread and were told to retract the
hand only when the pain became intolerable. A 15-min time
limit was set for safety reasons; for subjects not withdraw-
ing within this time, 15 min was recorded.
Adverse events
Four of the most often observed adverse events associated
with opioids (nausea, drowsiness, pruritus, euphoria) were
monitored using a visual analog scale (line length 100 mm;
0 mm “not at all,” 100 mm “extremely strong”). Scores
were measured in millimeters and evaluated as deviations
from baseline (0 mm). Other possible adverse events were
asked for and recorded, but not quantified.
Calculations and statistics
Maximal effects (Emax) for dynamic pupillometry, adverse
events of oxycodone and the cold pressor test were
obtained from the raw data as the difference from the basal
value obtained at time 0 before the application of oxy-
codone. Areas under the effect curve (AUECs) were
calculated using the trapezoidal rule. The areas were
calculated using the value at time 0 (before the application
of oxycodone) as the basis. The areas reflecting the
pharmacodynamic effect of oxycodone were marked with
a positive prefix.
Statistical evaluations were performed with SigmaStat
3.5 software (Scientific Solutions, Pully Lausanne, Switzer-
land). Multiple group means were compared by one-way
analysis of variance. In the case of significance, differences
between the individual treatments were assessed using the
Sidak–Holm test. Repeated measures (see Figs. 4 and 5)
were analyzed using a one-way repeated measures analysis
of variance followed by Tukey’s test. The difference
between the values in patients pretreated with placebo vs
0 for the parameters drowsiness, euphoria, pruritus, and
nausea (see Table 3) was tested using a t test. All tests were
used as two-sided tests. The level of significance was set to
p=0.05. Data are presented as mean ± SD except for the
figures, where mean ± SEM are given.
Results
Pharmacokinetics of oxycodone and oxycodone metabolites
The kinetic parameters obtained for oxycodone under the
different pre-treatments are given in Fig. 3 and Table 1.
Compared with placebo, pre-treatment with paroxetine did
not significantly affect the kinetics of oxycodone. In
contrast, pre-treatment with ketoconazole was associated
with a higher Cmax (increase by 77%) and AUC (increase
by 146%) of oxycodone compared with placebo, demon-
strating the importance of CYP3A4 in oxycodone metab-
olism. In contrast, the half-life of oxycodone was not
affected by any of the pre-treatments.
Compared with placebo, pretreatment with ketoconazole
was associated with a decrease in Cmax for noroxycodone
(5.41±0.72 vs 9.83±0.43 ng/mL, p<0.05), but had no
effect on the Cmax of oxymorphone (0.81±0.06 vs 0.71±
0.07 ng/mL). In contrast, in comparison to placebo,
pretreatment with paroxetine was associated with a de-
crease in the Cmax of oxymorphone (0.44±0.02 vs 0.71±
0.07 ng/mL, p<0.05), but had no effect on the Cmax of
noroxycodone (9.32±0.52 vs 9.83±0.43 ng/mL).
Effect of oxycodone on pupillometry
Pre-treatment with ketoconazole or paroxetine in the
absence of oxycodone had no significant effect on any of
the variables determined (pupil diameter, time to maximal
constriction, pupil amplitude, and pupil redilatation time;
Fig. 4). As expected, treatment with oxycodone alone
affected all variables assessed (see placebo in Table 2,
Fig. 4). These effects of oxycodone were maximal at the 2-
h time point (Fig. 4). Since no earlier time points have been
assessed (this is true for all pharmacodynamic measure-
ments), it is possible that the maximal pharmacodynamic
effect of oxycodone has been missed. In comparison to
placebo, pre-treatment with ketoconazole was associated
with a more accentuated and a longer lasting contraction of
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Fig. 3 Pharmacokinetics of oxycodone. Subjects were pre-treated
with placebo, paroxetine or ketoconazole before ingesting a single oral
dose of oxycodone (0.2 mg/kg body weight). Ketoconazole increased
the exposure to oxycodone, whereas the effect of paroxetine was not
different from that of placebo
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the pupil (Table 2, Fig. 4a–c) and also with a shorter and
longer lasting shortening of the redilatation time (Table 2,
Fig. 4d). In contrast to ketoconazole, pre-treatment with
paroxetine was associated with a block of the effects of
oxycodone on pupil diameter and amplitude as well as time
to maximal constriction and velocity of pupil redilatation
(Table 2, Fig. 4).
Effect on cold pressor test
Treatment with oxycodone was associated with a signifi-
cant prolongation of the immersion period at 2 h after
ingestion of oxycodone (Fig. 5). Pre-treatment with
ketoconazole accentuated the analgetic effect of oxycodone,
leading to an increase in the immersion period starting at
2 h and lasting up to 6 h after ingestion of oxycodone. In
contrast, pre-treatment with paroxetine prevented the
analgetic activity of oxycodone. The corresponding values
for the area under the effect curve (AUEC) were
(mean ± SD) 512±324 for placebo (p<0.05 vs paroxetine),
208±192 for paroxetine and 1,046±1,199 s × h for
ketoconazole (p<0.05 vs paroxetine) pretreatment. The
values for the maximal effect (Emax) were 162±221 for
placebo, 54±34 for paroxetine and 220±226 s for ketoco-
nazole (p<0.05 vs paroxetine) pretreatment.
Adverse events
No severe adverse events were reported by the study
subjects. Four events were specifically recorded, drowsi-
ness, euphoria, pruritus, and nausea. Compared with zero
(no effect), Emax was increased for drowsiness and
euphoria, and AUEC for drowsiness for pretreatment with
placebo (Table 3). Pre-treatment with ketoconazole accen-
tuated the effect of oxycodone on drowsiness and was
associated with nausea and pruritus, but did not affect the
effect of oxycodone on euphoria (Table 3). In comparison,
pre-treatment with paroxetine was not significantly differ-
ent from placebo (Table 3).
Discussion
Our study shows that inhibition of CYP3A4 by ketocona-
zole increases the exposure to oral oxycodone as well as
many of its pharmacodynamic effects. In contrast, inhibi-
tion of CYP2D6 by paroxetine did not increase oxycodone
exposure, but attenuated some of the pharmacodynamic
effects of oxycodone.
Regarding the effect of reduced CYP2D6 activity on
oxycodone metabolism and action, the results of our study
are in agreement with those of Heiskanen et al. and
Grönlund et al. in healthy volunteers [9, 23] and those of
Lemberg et al. and Zwisler et al. in patients treated with
oxycodone [12, 24]. These studies showed that patients or
probands with inhibited CYP2D6 [9, 23, 24] or CYP2D6
slow metabolizers [12] have decreased formation of oxy-
morphone with or without only a small increase in
oxycodone exposure and there is no significant effect on
the analgetic activity of oxycodone. In a second study, in
which Zwisler et al. investigated the kinetics and dynamics
of oxycodone in healthy CYP2D6 extensive and poor
metabolizers [11], the observed changes in oxycodone
kinetics were also associated with dynamic changes. In this
study, the analgetic effect of oxycodone was more
accentuated in CYP2D6 extensive compared with poor
metabolizers, suggesting an analgetic effect of oxymor-
phone. Taking into consideration all currently available
studies on this subject, however, the available data indicate
that impaired activity of CYP2D6 (by administration of
CYP2D6 inhibitors or by enzyme polymorphisms) is
associated with only small changes in oxycodone pharma-
cokinetics, which do not usually result in altered oxycodone
pharmacodynamics.
Table 1 Pharmacokinetic parameters of oral oxycodone (0.2 mg/kg body weight) in healthy volunteers (n=12) pre-treated with placebo, three
doses of paroxetine (20 mg per dose) or ketoconazole (200 mg per dose). Data are given as mean ±SD
Parameter Placebo Paroxetine Ketoconazole
Cmax (ng/mL) 15.0±4.5 15.1±7.3 26.5±5.5
a
Tmax (h) 1.25±.80 1.00±0.42 1.04±0.89
Elimination rate constant λz (h
−1) 0.109±0.017 0.112±0.014 0.119±0.014
t½ (h) 6.62±1.59 6.32±0.90 5.89±0.69
AUC0-48h (ng × mL
−1 × h) 75.6±25.3 75.0±26.7 186±69a, b
AUC01 (ng × mL−1 × h) 76.8±25.3 75.6±26.7 187±69a, b
a p<0.05 vs paroxetine
b p<0.05 vs placebo
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In our study, changes in oxycodone pharmacodynamics
associated with CYP2D6 inhibition cannot be judged,
because the pharmacodynamic effects of paroxetine inter-
fered with those of oxycodone. While pre-treatment with
paroxetine revealed no significant effect on pupil diameter,
it blunted the effects of oxycodone on the pupil. In other
studies, SSRIs such as fluoxetine, citalopram or paroxetine
have been described to increase pupil diameter [25–27]. To
the best of our knowledge, the effects of SSRIs on pupil
reaction associated with opioids have so far not been
described. The miotic reaction of opioids is believed to be
mediated by the parasympathetic nervous system [28, 29],
most probably by stimulation of preganglionic cholinergic
neurons in the Edinger–Westphal nucleus [30]. On the other
hand, the effects of SSRIs on pupil reaction is considered to
be mediated by serotoninergic stimulation of central 5HT1A
receptors, which is associated with synaptic release of
noradrenalin followed by stimulation of postsynaptic
alpha2-adrenoreceptors [27, 31]. Stimulation of alpha2-
adrenoreceptors in the Edinger–Westphal nucleus counter-
acts cholinergic stimulation associated with opioids [31]
and can therefore explain the blunted pupillary reaction of
oxycodone after pre-treatment with paroxetine. This finding
may be of clinical importance, since patients treated with
opioids may have normally sized, unreactive pupils when
they are concomitantly treated with an SSRI.
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Fig. 4 Pupillometric assessment. The data were obtained using a
desktop pupillometer (Compact Integrated Pupillograph; Amtech,
Hamburg, Germany) as described in Materials and methods. The
pupillary reflex was induced by a light stimulus of 250 ms. n=12
subjects, results presented as mean ± SEM
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Effects of SSRIs on pain and/or possible interferences
with opioids have so far been reported in only a few
studies. While SSRIs such as fluoxetine and paroxetine
have been found to exhibit analgetic properties in mice
[32–34], fluoxetine itself revealed no analgetic properties in
humans [35]. When combined with morphine, the analgetic
effect of morphine was marginally improved by fluoxetine
in the study by Erjavec et al. [35], but decreased in another
study [36]. In comparison, in our study, paroxetine blunted
the effect of oxycodone on the cold pressor test. Further
studies are necessary to be able to draw firm conclusions
about possible interferences between SSRIs and the
pharmacodynamic effects of opioids.
Regarding the effect of CYP3A4 inhibition, our findings
are in good agreement with those of Hagelberg et al. [13], who
demonstrated that CYP3A4 inhibition by voriconazole
increases exposure to and the dynamic effects of oxycodone.
In comparison to the study by Hagelberg et al. [13], who
described a 2.7- to 5.6-fold increase in the AUC of
oxycodone after pre-treatment with voriconazole, the effect
of ketoconazole on oxycodone exposure was slightly less
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Fig. 5 Analgetic effect of oxycodone. The cold pressor test was used
to measure pain tolerability as described in Materials and methods. n=
12 subjects, results presented as mean ± SEM.*p<0.05 vs latency time
at t=0 within the same treatment group
Parameter Placebo Paroxetine Ketoconazole
Pupil diameter
−Emax (mm × 10−2) 144±97 49±55a 235±76a, b
−AUEC (mm × 10−2 × h) 744±987 −101±682a 1,680±760a, b
Latency of pupil reaction
−Emax (ms) 4.3±4.5 4.9±4.2 6.7±3.5
−AUEC (ms × h) 17.9±44.7 18.7±60.6 41.1±43.3
Amplitude of pupil reaction
−Emax (mm × 10−2) 41.3±31.9 33.8±21.5 83.9±32.2a, b
−AUEC (mm × 10−2 × h) 173±322 146±239 599±305a, b
Time to pupil constriction
−Emax (ms) 20.9±16.3 10.6±10.7 38.3±15.9a, b
− AUEC (ms × h) 62±157 −33±155 255±135a, b
Pupil redilatation
−Emax (ms) 37.1±24.2 17.9±21.5 61.5±23.2a, b
−AUEC (ms2) 141±291 −63±230 384±256b
Table 2 Dynamic pupillometry.
The papillary reflex was induced
by a light stimulus of 250 ms
using a desktop pupillometer
(Compact Integrated Pupillo-
graph; Amtech, Hamburg, Ger-
many) as described in Materials
and methods. The pharmacolog-
ical effect of oxycodone always
has a positive prefix. n=12
subjects, results presented as
mean ± SD
a p<0.05 vs placebo
b p<0.05 vs paroxetine
Table 3 Adverse events of oxycodone after different pre-treatments.
Adverse events were recorded using visual analog scales (0 to
100 mm). The pharmacological effect of oxycodone has always a
positive prefix. n=12 subjects, results presented as mean ± SEM
Parameter Placebo Paroxetine Ketoconazole
Drowsiness
−Emax (mm) 44.4±30.1a 29.2±24.9 53.7±23.9
−AUEC (mm × h) 171±260a 39±200 309±198b
Euphoria
−Emax (mm) 14.8±13.5a 14.4±13.9 7.7±10.0
−AUEC (mm × h) 74±169 67±141 −39±112
Pruritus
−Emax (mm) 0.7±1.4 4.3±10.4 17.7±22.9c
−AUEC (mm × h) −19.3±75.5 13.1±31.2 52±122
Nausea
−Emax (mm) 9.2±24.6 17.1±28.8 36.8±42.3
−AUEC (mm × h) 36.3±97.0 14.0±23.6 144±166b, c
a p<0.05 placebo vs zero
b p<0.05 vs paroxetine
c p<0.05 vs placebo
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accentuated in our study (2.4-fold increase in AUC and 1.8-
fold increase in Cmax). Nevertheless, similar to the findings
by Hagelberg et al. [13], the observed increase in oxycodone
exposure was associated with pharmacodynamic changes, in
particular concerning pupillometry. The results of our study
also agree with statements made by Lalovic et al. [10],
namely that CYP3A4-mediated N-demethylation is quanti-
tatively the most important metabolic pathway of oxycodone
and that the analgetic activity of oxycodone is primarily
associated with the mother substance. As shown by Zwisler
et al., a significant contribution of oxymorphone can be
demonstrated in extensive CYP2D6 metabolizers under
experimental [11], but not under clinical conditions [12].
Based on the current and previous studies [13–15], drug
interactions with oxycodone can be expected to have
clinical consequences. Inhibition of CYP3A4 increases the
exposure to oxycodone 2- to 5-fold and must therefore be
taken into account in patients treated with this drug.
Similarly, induction of CYP3A4 can be expected to be
associated with a decrease in the analgetic effect of
oxycodone. This is also the case for other opioids that are
primarily metabolized by CYP3A4, such as methadone
[37], fentanyl [38], and buprenorphine [39]. Regarding the
high inter-individual variability of CYP3A4 activity [40,
41], it is important to start oxycodone and the other opioids
primarily metabolized by CYP3A4 at a low dosage and to
perform a careful up-titration, until sufficient analgesia is
obtained. While CYP2D6 inhibition does not significantly
affect the kinetics and dynamics of oxycodone (this study
and [9]) and oxycodone is also effective and safe in
CYP2D6 poor metabolizers [11, 12], there are so far no
data on the efficacy and safety of oxycodone in ultra-rapid
CYP2D6 metabolizers. CYP2D6 ultra-rapid metabolizers
should be up-titrated very carefully with oxycodone to
avoid adverse reactions due to increased formation of the
active metabolite oxymorphone. Such reactions have been
described for CYP2D6 ultra-rapid metabolizers treated with
codeine [42, 43] or tramadol [44].
In conclusion, inhibition of CYP3A4 by ketoconazole
increases the exposure to and the pharmacodynamic effects
of oxycodone. Inhibition of CYP2D6 by paroxetine does
not significantly increase oxycodone exposure, but influen-
ces oxycodone pharmacodynamics through its own phar-
macodynamic activity. Paroxetine is therefore not an ideal
CYP2D6 inhibitor for studies in which the central effects of
drugs are important variables. Pharmacokinetic and dynam-
ic changes associated with CYP3A4 inhibition may be
clinically important in patients treated with oxycodone.
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